Amicus Therapeutics (NASDAQ:FOLD) Hits New 1-Year Low – Should You Sell?

Amicus Therapeutics, Inc. (NASDAQ:FOLD)’s share price hit a new 52-week low during trading on Friday . The company traded as low as $8.97 and last traded at $9.01, with a volume of 512437 shares traded. The stock had previously closed at $9.46.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. Cantor Fitzgerald upped their price objective on shares of Amicus Therapeutics from $20.00 to $21.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Morgan Stanley reissued an “equal weight” rating and set a $12.00 target price (down previously from $17.00) on shares of Amicus Therapeutics in a research note on Friday, December 13th. JPMorgan Chase & Co. raised their price target on shares of Amicus Therapeutics from $16.00 to $17.00 and gave the company an “overweight” rating in a research report on Tuesday, November 12th. StockNews.com downgraded Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. Finally, Guggenheim increased their target price on Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, Amicus Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $16.88.

Amicus Therapeutics Trading Down 4.7 %

The company has a debt-to-equity ratio of 2.18, a current ratio of 3.15 and a quick ratio of 2.42. The company has a fifty day moving average of $9.90 and a 200-day moving average of $10.54. The firm has a market capitalization of $2.70 billion, a PE ratio of -26.53 and a beta of 0.62.

Insider Buying and Selling at Amicus Therapeutics

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,901 shares of Amicus Therapeutics stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $12.50, for a total value of $98,762.50. Following the transaction, the chief executive officer now owns 886,654 shares of the company’s stock, valued at approximately $11,083,175. The trade was a 0.88 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Over the last ninety days, insiders have sold 22,901 shares of company stock valued at $259,863. 2.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of FOLD. Xponance Inc. increased its holdings in shares of Amicus Therapeutics by 5.3% during the second quarter. Xponance Inc. now owns 18,555 shares of the biopharmaceutical company’s stock worth $184,000 after buying an additional 936 shares in the last quarter. Hazlett Burt & Watson Inc. increased its position in shares of Amicus Therapeutics by 156.9% during the third quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 1,569 shares during the last quarter. Arizona State Retirement System raised its holdings in shares of Amicus Therapeutics by 2.6% in the 2nd quarter. Arizona State Retirement System now owns 62,020 shares of the biopharmaceutical company’s stock worth $615,000 after purchasing an additional 1,577 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Amicus Therapeutics by 21.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,727 shares of the biopharmaceutical company’s stock valued at $115,000 after purchasing an additional 1,884 shares during the period. Finally, OLD Second National Bank of Aurora purchased a new stake in shares of Amicus Therapeutics in the third quarter worth about $26,000.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.